Stéphane Boissel, Chief Executive Officer

Stephane studied management and finance at the University of Lyon, France, graduated at Paris-Dauphine and obtained his MBA from the University of Chicago (Booth GSB), USA.

Stéphane is a highly capable executive with strong experience in both investment banking and the biotech immunotherapy space. In the early part of his career, from 1990 to 2002, Stéphane worked at PWC and then for the investment banking group Lazard, where he mostly worked in principal investment in France, Singapore and Hong Kong.

Thereafter, he worked at Innate Pharma SA from 2002 to 2010, firstly as CFO and then as EVP and CFO. From 2010 to 2014, he was Deputy-CEO of Transgene SA. During his tenure at both Transgene and Innate Pharma, he led several rounds of private and public placement and negotiated several international business deals.

Stephane was also a member of the Board of Directors of Erytech Pharma SA from 2005 to 2010. In 2014, he was CEO of Genclis, a molecular diagnostic company, before joining TxCell as Chief Executive Officer in April 2015. He is Chairman of the Board of Directors of Elsalys Biotech SAS.

Raphael Flipo, SVP, Chief Financial Officer

Raphaël graduated from business school (EDHEC, Nice) with a specialization in corporate finance, and he holds a Master’s Degree in tax and business law.

He acquired 4 years experience as Financial Auditor in PricewaterhouseCoopers and he spent 5 years as Finance Manager France in Lionbridge Technologies.

Raphaël joined TxCell as Chief Financial Officer in May 2013.

François Meyer, Chairman of the Board and Head of Research

François graduated from the Swiss Federal Institute of Technology (ETHZ), in Zurich, and studied Biochemistry and Molecular Biology at the University of Zurich.

He received his Ph.D. from the Institute for Molecular Biology. He has spent over 20 years in the pharmaceutical industry.

During the early part of his career, he held various executive positions in R&D at Ciba-Geigy Pharma, wherehe headed the Molecular Genetics department in the newly formed Biotechnology division and at Sandoz Pharma, where he led the Gene and Cell Therapy business.

After joining Rhone Poulenc Rorer, where he has been head of Global Research, he became head of R&D at Aventis Pharma, France after the merger with Hoechst and lately CEO of Centelion, a biopharmaceutical affiliate company of Aventis Pharma.

He has been member of the board of directors of several privately owned biopharmaceutical companies in the US and in Europe.

François joined TxCell as CEO in 2011 and became Chairman of the Board in 2012 and Head of Research in 2016.